36 completed, 16 active not recruiting, 12 recruiting, 7 terminated. 77 Phase 3, 3 Phase 2.
By phase and status
Follow Chronic Lymphocytic Leukemia: new trials by email Literature Review of Chronic Lymphocytic Leukemia trials Research Report on Chronic Lymphocytic Leukemia
Trials (filtered) newest first · largest first
All 77 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 620 | 2026-08-03 | 2026-08-31 |
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Zanubrutinib, Sonrotoclax, Computed Tomography - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 3 | Recruiting | 466 | 2026-04-30 | 2026-11-03 |
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Sonrotoclax, Zanubrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 500 | 2026-01-22 | 2026-09-28 |
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Tacabrutideg, Pirtobrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 500 | 2025-09-04 | 2026-09-28 |
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Sonrotoclax, Obinutuzumab, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 630 | 2025-06-11 | 2026-10-23 |
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
BGB-16673, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 153 | 2025-05-29 | 2026-08-24 |
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Tacabrutideg, Bendamustine, Idelalisib - CLL, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 250 | 2025-04-10 | 2026-09-28 |
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Venetoclax, Acalabrutinib, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 170 | 2024-08-05 | 2026-04-09 |
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
American Ginseng, Placebo Administration, Questionnaire Administration - Malignant Solid Neoplasm, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 222 | 2024-08-01 | 2026-10-20 |
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Nemtabrutinib, Ibrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 1200 | 2023-12-13 | 2026-10-13 |
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Nemtabrutinib, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 300 | 2023-03-16 | 2026-03-16 |
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
Pfizer Bivalent COVID-19 Vaccine, Moderna Bivalent mRNA vaccine - HIV, Organ Transplantation | Phase 3 | Active not recruiting | 960 | 2022-12-01 | 2025-10-03 |
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Pirtobrutinib, Ibrutinib - Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic | Phase 3 | Recruiting | 737 | 2022-07-22 | 2026-08-17 |
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
Obinutuzumab, Venetoclax, Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | 202 | 2022-04-19 | 2026-08-20 |
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Pirtobrutinib, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 282 | 2021-09-23 | 2026-09-25 |
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Pirtobrutinib, Venetoclax, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 600 | 2021-09-20 | 2026-01-29 |
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells - Diffuse Large B Cell Lymphoma, Burkitt Lymphoma | Phase 3 | Unknown | 24 | 2021-09-14 | 2023-07-25 |
Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation
Zebutinib&BR or Zebutinib&FCR - Chronic Lymphocytic Leukemia | Phase 3 | Unknown | 45 | 2021-09-01 | 2021-07-28 |
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Pirtobrutinib, Idelalisib, Bendamustine - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 238 | 2021-03-09 | 2026-04-24 |
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 247 | 2021-03-02 | 2026-11-02 |
Showing 20 of 77. Sign in to see all of them.
Narrower conditions
Leukemia, Lymphocytic, Chronic, B-Cell (77) · Lymphoma, Non-Hodgkin (10) · Multiple Myeloma (6) · Lymphoma, B-Cell (5) · Recurrence (5) · Hematologic Diseases (4) · Leukemia (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, Mantle-Cell (4) · Neoplasms (4) · Anemia (3) · Hodgkin Disease (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3)
Broader conditions
Chronic Disease (77) · Disease Attributes (77) · Hemic and Lymphatic Diseases (77) · Immune System Diseases (77) · Immunoproliferative Disorders (77) · Lymphatic Diseases (77) · Lymphoproliferative Disorders (77) · Neoplasms by Histologic Type (77) · Pathologic Processes (77) · Pathological Conditions, Signs and Symptoms (77) · Leukemia, Lymphoid (76) · Leukemia, B-Cell (75) · Hematologic Diseases (73) · Leukemia (73) · Neoplasms (73)
Interventions
Rituximab (23) · ibrutinib (18) · Bendamustine Hydrochloride (17) · venetoclax (16) · obinutuzumab (14) · fludarabine (13) · Cyclophosphamide (11) · Chlorambucil (10) · acalabrutinib (9) · idelalisib (9) · pirtobrutinib (6) · zanubrutinib (4) · Mycophenolic Acid (3) · fludarabine phosphate (3) · ofatumumab (3)
Sponsors
German CLL Study Group (11) · Gilead Sciences (6) · BeOne Medicines (5) · Acerta Pharma BV (4) · Loxo Oncology, Inc. (4) · National Cancer Institute (NCI) (4) · AbbVie (3) · Hoffmann-La Roche (3) · Janssen Research & Development, LLC (3) · Pharmacyclics LLC. (3) · TG Therapeutics, Inc. (3) · BeiGene (2) · Merck Sharp & Dohme LLC (2) · SecuraBio (2) · Alliance for Clinical Trials in Oncology (1)
Countries
United States (50) · Germany (36) · United Kingdom (35) · Spain (34) · Australia (33) · France (33) · Poland (31) · Italy (30) · Belgium (28) · Canada (27) · Sweden (23) · Czechia (22) · China (21) · Israel (21) · Austria (20)
Top investigators
Michael Hallek, MD (6) · Barbara Eichhorst, MD (2) · Barbara Eichhorst, MD, Prof. (2) · Tait D Shanafelt (2) · Adel Habib, MD (1) · Anna Fink, MD (1)
Results publications
PMID 34865212, PMID 40266025, PMID 28751558, PMID 29880603, PMID 31196847, PMID 32599655, PMID 35014928, PMID 35377947, PMID 36617990, PMID 38502198, PMID 38598745, PMID 38620092, PMID 39563886, PMID 40396505, PMID 41749915, PMID 16219797, PMID 17389338, PMID 19605849, PMID 23525797, PMID 24450857, PMID 24797299, PMID 24916506, PMID 26293380, PMID 26377031, PMID 26639149, PMID 26655421, PMID 27233802, PMID 27374465, PMID 28257752, PMID 28804126, PMID 28916311, PMID 29562156, PMID 29749403, PMID 30254130, PMID 30287523, PMID 30522969, PMID 30523712, PMID 30995176, PMID 31044267, PMID 31248843, PMID 31365801, PMID 31455851, PMID 31729982, PMID 31875923, PMID 32042081, PMID 32071431, PMID 32207333, PMID 32305093, PMID 32459600, PMID 32499241
NIH funding
2023 (6), 2015 (4), 2025 (3), 2005 (2), 2014 (2), 2018 (2), U10CA180820 (2), 2009 (1), 2017 (1), 2019 (1), P01CA018029 (1), P30CA015704 (1), R01CA193541 (1), U10CA021115 (1), U10CA180821 (1)